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Motivations
Drug development is a costly and failure-prone 
process and, in recent years, pharmaceuti-
cal industry has experienced a difficult period 
whereby productivity has not kept pace with in-
creases in research and development costs. As 
a consequence, quite recently research efforts 
focused on a novel paradigm for drug devel-
opment, named drug repurposing, to discover 
novel pharmacological applications of existing 
drugs. Computational approaches for drug re-
positioning focused mainly on small-scale appli-
cations, such as the analysis of specific classes 
of drugs or drugs for specific diseases. Large-
scale applications, involving a relatively large 
number of drugs and diseases, count only a few 
examples. Despite the availability of many drug 
repositioning methods, they all suffer from a se-
rious limitation: the inference task is performed 
in an inhomogeneous similarity space induced 
by the relationships existing between drugs and 
a second type of entity (e.g. disease, target, or 
ligand set), thus making difficult the integration 
of multiple sources of biomolecular and chemi-
cal data into a homogeneous pharmacological 
space.
Methods
To overcome this limitation we propose a gener-
al framework based on bipartite networks projec-
tions for the construction of homogeneous phar-
macological spaces. The nature of these network 
structured projected spaces allows the applica-
tion of prediction algorithms to homogeneous 
pharmacological spaces and improves the inte-
gration of different chemical, biomolecular and 
clinical sources of information. At the core of the 
proposed approach there is the notion of ho-
mogeneous pharmacological similarity space 
defined as a collection of similarities between 
drugs induced by common relationships be-
tween drugs and a second type of suitable en-
tities (i.e. drug-protein target). The reconciliation 
between these heterogeneous similarity spaces 
is performed by means of a network projection 
operation enabling the reduction of a network 
composed by two types of nodes (i.e. drugs and 
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drug targets) to a network composed only by 
drugs. A key feature of the proposed framework 
is its ability to integrate networks of different sizes, 
enabling the combination of both high and low 
coverage networks and resulting into a progres-
sively enriched pharmacological similarity net-
work. We also propose a novel and very fast ker-
nelized semi-supervised network based method 
for ranking drugs according to their likelihood to 
belong to a given therapeutic category.
Results
We evaluated the proposed approach by inte-
grating two pharmacological similarity spaces 
accounting, respectively, for chemical simi-
larity and drug-targets interaction similarity, in 
order to rank about 1300 U.S. Food and Drug 
Administration (FDA) approved drugs accord-
ing to DrugBank 3.0 therapeutic categories. 
The experimental setup is based on a canoni-
cal 5-fold cross validation scheme repeated 10 
times. The analysis of the precision at fixed recall 
levels (see Figure), shows that the integration of 
pharmacological spaces constructed through 
the proposed network projections significantly 
enhances the results obtained with different 
network-based ranking methods. Moreover our 
proposed kernelized semi-supervised method 
for ranking drugs according to a given therapeu-
tic category is at least comparable in terms of 
AUC and precision at fixed recall, and orders of 
magnitude faster than state-of-the-art ranking 
methods. Despite a thorough analysis of the re-
sults relative to each therapeutic category is out 
of the scope of this preliminary investigation, the 
analysis of the top ranked false positives predict-
ed in three drug categories shows that our pro-
posed approach can be successfully applied 
to discover potential drug candidates for novel 
therapeutic indications.
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